B-cell lymphoma can be unpredictable. Some types spread very quickly, while others resist treatment or tend to return over time. But research into this cancer keeps growing, which has lymphoma experts and doctors feeling hopeful about the future of B-cell lymphoma treatment.
"The natural history of large B-cell lymphomas is really changing before our eyes because of new, incredible, exciting technologies that we have," says David Greenberg, MD, a hematologist-oncologist at Hackensack Meridian Health Cancer Center in Neptune, New Jersey.
Here's what to know about the latest research into B-cell lymphoma and what it means for you.
Earlier Detection
There are no screening tests to check for lymphoma if you do not have symptoms. This is different from cancers like breast or colon cancer, for which there are tests you can do regularly.
Doctors usually identify B-cell lymphoma after you or a health care provider notices a swollen lymph node. Other symptoms may include fever, night sweats, or unexplained weight loss.
A biopsy is necessary to confirm the diagnosis. During this test, a surgeon removes a lymph node sample for laboratory analysis. Doctors can then determine if you have B-cell lymphoma and identify the specific type.
So how could doctors find and track B‑cell lymphoma sooner and more easily? “As with all diseases, the future is going to be blood tests,” says Greenberg.
For example, cancer cells leave tiny pieces of their genetic code in your blood. Doctors can use a test called a "liquid biopsy" to look for these signals. The main signal they look for is called circulating tumor DNA (ctDNA). Think of this as a tiny "genetic footprint" of cancer.
However, doctors use this kind of testing mainly for certain large B-cell lymphomas at specialty centers, and these tests still do not replace a tissue biopsy, which remains the most reliable way to diagnose lymphoma.
Better Monitoring After Treatment
After you’ve been diagnosed, doctors can use several methods to see how well lymphoma treatment is working, such as physical checkups, blood tests, and special body scans called PET-CT scans.
But doctors may also use liquid biopsies to help manage care for certain types of B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL). In this case, the tests can help doctors see if any cancer is still present after you finish your treatment.
Sometimes, a scan taken after your first treatment might show a suspicious spot, but it may be too hard to get a tissue sample to check it. In these cases, doctors can use a blood test called ctDNA-MRD instead. This test helps them figure out if that spot is actually active cancer that needs more treatment.
“We might be able to identify patients that are at higher risk of relapse than we initially thought,” Greenberg says.
In another example, multigene panel testing (MGPT) testing is another lab test that reads the DNA in your lymphoma tissue to find many genetic mistakes all at once. By looking at these specific genes, doctors can better understand what type of cancer you have and help refine your treatment plan and clinical trial options.
Researchers are still studying these tests to learn more about how these can help understand and predict how lymphoma acts in the body. This can help doctors see how useful these tools will be for future patient care.
Promising Treatment Advances
Researchers are always looking for better ways to treat B-cell lymphoma.
“Up until 10 years ago, the standard of care [for relapsed lymphoma] was more chemo and an autologous stem cell transplant, where you’re getting your own stem cells. But now we have cooler and better treatments available,” says Greenberg.
Because cancer cells can find ways to survive and grow even after treatment, in some cases doctors may combine standard treatments with newer treatments like targeted therapy or immunotherapy. We explain these new advances in the next sections.
Immunotherapy
Immunotherapy is a type of cancer treatment that helps your immune system identify and respond to lymphoma cells more effectively by activating it and guiding it directly to the cancer. In that way, immunotherapy uses your body’s natural defensive cells.
Examples of advances in immunotherapy for B-cell lymphoma include:
CAR T-Cell Therapy
CAR T-cell therapy takes some of your own T cells (immune cells that fight germs) and changes them in a lab to target a protein called CD19. When these cells go back into your body, they help your immune system recognize and target your cancer cells.
“They’re like Navy SEALs of the military, where they really go in, and they have a very specific mission, which is to kill your lymphoma cells,” says Greenberg. It can help people even if other treatments, including stem cell transplants, didn't work.
Doctors usually offer CAR T after one or two other treatments for lymphoma have not worked. The decision to use it often depends on how soon the cancer comes back.
Other types of CAR T treatments are still in clinical trials. These are:
CAR-NK therapy: This is similar to CAR T, but instead of using T cells, it uses "natural killer" (NK) cells instead.
Anti-CD20 CAR T-cell therapy: This treatment is designed to target only the CD20 protein.
Dual-target CAR T-cell therapy: This treatment is designed to target both CD19 and CD20 at the same time.
Bispecific Antibodies (BsAbs)
These are lab-made proteins that act like a bridge. They attach to a T cell on one side and a cancer cell on the other, bringing your immune cells close enough to attack the cancer. Several of these are now approved by the FDA for people who have already tried at least two other treatments.
Compared to other therapies, these drugs have a different set of side effects and, in some cases, lower rates of certain severe reactions than other treatments. More research is happening now to see how well these work for patients who have already tried other treatments.
Targeted Therapy
Targeted therapy is a type of cancer treatment that uses drugs to find and disrupt specific genes, proteins, or the surrounding environment that cancer cells need to grow and spread. Because these medicines focus only on cancer cells, they may do less damage to healthy cells and cause different side effects than standard chemotherapy.
Some examples of targeted therapy for different cancers, including lymphoma, are antibody-drug conjugates (ADCs), Bruton tyrosine kinase (BTK) inhibitors, and BCL‑2 blockers. These treatments continue to evolve.
For example, in 2026, the FDA approved the BCL-2 blocker Beqalzi (sonrotoclax) as a treatment for adults with a type of B-cell lymphoma called mantle cell lymphoma (MCL) that has either returned after treatment or hasn’t responded to treatment.
Examples of treatments that combine targeted therapy with other medications for lymphoma include:
ViPOR
“ViPOR” stands for venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone (Deltasone, Sterapred, and others), obinutuzumab (Gazyva), and lenalidomide (Revlimid).
Scientists are testing this new approach that uses a combination of these five drugs to block the cancer's survival routes all at once. This treatment may work best for people with certain aggressive or high-risk types of lymphoma. Experts are doing larger studies to confirm how well this works.
Tafasitamab and lenalidomide
Tafasitamab (Monjuvi) is a target drug and lenalidomide (Revlimid) is an immunotherapy drug. Doctors may use these two together as a standard treatment if your lymphoma has returned.
What's Ahead
In the coming years, diagnostic tests and life-saving treatments for B-cell lymphoma will continue to build on these research findings and advances. "I think this is only the beginning of this technology and where it's going to go," Greenberg says.
If you are interested in learning about clinical trials near you, you can visit ClinicalTrials.gov and search for “B‑cell lymphoma.”
